Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

ClinicalTrials.gov ID: NCT03907852

Public ClinicalTrials.gov record NCT03907852. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 4, 2026, 7:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 Single Arm Open-Label Clinical Trial of Gavocabtagene Autoleucel (Gavo-cel) in Patients With Advanced Mesothelin-Expressing Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Gavocabtagene autoleucel (gavo-cel; TC-210) is a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex. This Phase 1/2 study aims to establish the recommended Phase 2 dose (RP2D) and subsequently evaluate the efficacy of gavo-cel, with and without immuno-oncology agents, in patients with advanced mesothelin-expressing cancers, with overall response rate and disease control rate as the primary Phase 2 endpoints.

Study identification

NCT ID: NCT03907852
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: TCR2 Therapeutics; Industry
Enrollment: 57 participants

Conditions and interventions

Conditions

Interventions

Biological · Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 14, 2019
Primary completion: Nov 18, 2024
Completion: Nov 1, 2028
Last update posted: Aug 26, 2025

2019 – 2028

United States locations

U.S. sites: 10
U.S. states: 9
U.S. cities: 9

Facility	City	State	ZIP	Site status
University of California, San Francisco	San Francisco	California	94143	—
University of Miami Sylvester Cancer Center	Miami	Florida	33136	—
University of Chicago Medical Center	Chicago	Illinois	60637	—
National Cancer Institute	Bethesda	Maryland	20814	—
Columbia University Medical Center	New York	New York	10032	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
Duke University	Durham	North Carolina	27705	—
University of Pennsylvania	Philadelphia	Pennsylvania	19104	—
SCRI Oncology Partners	Nashville	Tennessee	37203	—
University of Texas MD Anderson Cancer Center	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03907852, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 26, 2025 · Synced Sep 4, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03907852 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →